While the impairment of the anticancer immune response caused by the genetic abrogation of DC1s was previously described (such as in Batf3-/- mouse models) [12–14], the impact of the naturally-occurring decrease in DC1 proportions provoked by lung tumor development (reported here) on the anticancer immune response and cancer severity remained unaddressed. This evidence concerns the gene ZDHHC4 and cancer.